Medical Oncology Branch
Clinical Director of
CCR, NCI
Chief, GU/GYN Clinical Research Section
Principal Investigator

National Cancer Institute
9000 Rockville Pike
Building 10, Room 12N226
Bethesda, MD 20892

Phone: 301-496-4916
Fax: 301-402-0172
dahutw@mail.nih.gov

Dr. Dahut received his M.D. from Georgetown University in Washington, D.C. He completed clinical training in internal medicine at the National Naval Medical Center in Bethesda, Md., followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of NCI. Dr. Dahut worked as an attending physician in the NCI-Navy Medical Oncology Branch until 1995. He then joined the faculty of the Lombardi Cancer Center at Georgetown University before returning to the former NCI Medicine Branch in 1998 as head of the prostate cancer clinic. Dr. Dahut is the clinical director of CCR, NCI and chief of the GU/GYN Clinical Research Section in the Medical Oncology Branch. Dr. Dahut’s primary research interest has been in the development of novel therapeutic strategies for the treatment of adenocarcinoma of the prostate.

Dr. Dahut's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with prostate cancer, bladder cancer, or urothelial Cancer. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer NCI-12-C-0204 , NCT01683994

A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma NCI-12-C-0205, NCT01437488

NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-Resistant Prostate Cancer to Bone Treated With Either Docetaxel-Based Chemotherapy or Androgen Receptor (AR)-Directed Therapies NCI-12-C-0080, NCT01516866

A Phase II Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer NCI-12-C-0079, NCT01553188

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer NCI-10-C-0062, NCT01090765

A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) NCI-09-C-0195, NCT00942578

 Videocast/Podcast Details:

The quality of these videocasts is dependent on the speed of your Internet connection. Many videocasts are streamed directly to your computer by software on the NIH VideoCasting Web site. Others require that you have a standalone player installed on your computer to handle the streaming. If you do not have a standalone player installed or if you are having problems viewing the videocast, please visit http://videocast.nih.gov/faq/.

Some of the resources above require the use of a standalone player: Download Free RealPlayer